The IPO’s 2026 Draft Guidelines face strong critique for misquoting law and risking disruption to patent prosecution in pharmaceuticals; calls grow for immediate revision.
Legal Community Criticizes IPO's Draft Pharmaceutical Patent Guidelines (2026)
The Indian Patent Office's (IPO) Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, 2026, have come under sharp criticism from legal and industry experts for containing material errors, including misquotation of statutory provisions and misinterpretation of settled case law. The guidelines, intended to standardize examination practices, are seen as potentially disruptive to the consistency and predictability of pharmaceutical patent prosecution in India.
Key concerns include incorrect interpretation of Sections 3(d) and 3(e) of the Patents Act, 1970, particularly regarding the thresholds for 'enhancement of known efficacy' and 'mere admixtures'. The draft also appears to conflate novelty and inventive step assessments, risking arbitrary rejections. Experts argue that such ambiguities could lead to inconsistent decision-making and increased litigation burden.
For practitioners, the draft underscores the need to file detailed responses during examination, preemptively correcting misapplications of law. The backlash highlights the importance of stakeholder consultation in guideline formulation. The IPO is under pressure to revise the draft in consultation with IP professionals, academics, and industry bodies before finalization, to ensure alignment with statutory mandates and judicial precedents.
